Tonix Meds patents expiration
1. Tosymra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440631 | TONIX MEDS | Compositions for drug administration |
May, 2026
(2 years from now) | |
| US9283280 | TONIX MEDS | Compositions for drug administration |
May, 2026
(2 years from now) | |
| US8268791 | TONIX MEDS | Alkylglycoside compositions for drug administration |
May, 2026
(2 years from now) | |
| US9610280 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
| US11337962 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
| US9974770 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
| US10603305 | TONIX MEDS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
| US9211282 | TONIX MEDS | Formulations comprising triptan compounds |
Jul, 2031
(7 years from now) | |
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 25 January, 2019
Treatment: Acute treatment of migraine
Dosage: SPRAY;NASAL
More Information on Dosage
TOSYMRA family patents
2. Zembrace Symtouch patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537554 | TONIX MEDS | Pharmaceutical composition for treating migraine |
Jan, 2036
(11 years from now) | |
| US11364224 | TONIX MEDS | Pharmaceutical composition for treating migraine |
Jan, 2036
(11 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of migraine
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
ZEMBRACE SYMTOUCH family patents